Interaction Checker

Apps

Download from the AppStore

Download from Google Play

Interaction Checker
About Us
Mission Statement Meet the Team Steering Committee
Interaction Checkers
Interaction Checker Español Checker Français Checker Português Checker Interaction Checker Lite View All Checker
Prescribing Resources Videos Site News
Contact Us
Feedback Form Suggest a Drug
Support Us
Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Do Not Coadminister

Emtricitabine/Tenofovir alafenamide for PrEP (FTC/TAF, PrEP)

Lamivudine (3TC)

Quality of Evidence: Very Low

Summary:

Emtricitabine and tenofovir alafenamide used as PrEP are not expected to be coadministered with antiretrovirals. Emtricitabine/tenofovir alafenamide for PrEP should not be coadministered with lamivudine as emtricitabine may compete for metabolism with other cytidine analogues such as lamivudine.

Description:

Descovy should not be administered concomitantly with medicinal products containing lamivudine.
Descovy Summary of Product Characteristics, Gilead Sciences Ltd, April 2022.

Lamivudine should not be administered concomitantly with other cytidine analogues, such as emtricitabine.
Epivir Summary of Product Characteristics, ViiV Healthcare UK Ltd, February 2019.

View all available interactions with Emtricitabine/Tenofovir alafenamide for PrEP (FTC/TAF, PrEP) by clicking here.

SPONSORS
EDITORIAL SPONSORS
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
healthline-best-HIV-and-AIDS-apps-of-2019
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016
Cookie Policy Privacy Statement Terms & Conditions

Copyright © 2025 The University of Liverpool. All rights reserved.